Telix Pharmaceuticals Limited (TLX.AX)
| Previous close | 6.43 |
| Open | 6.60 |
| Bid | 6.21 x 993000 |
| Ask | 6.43 x 862200 |
| Day's range | 5.96 - 6.73 |
| 52-week range | 3.47 - 8.82 |
| Volume | |
| Avg. volume | 670,456 |
| Market cap | 1.779B |
| Beta (5Y monthly) | 2.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.22 |
| Earnings date | 23 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.72 |
- GlobeNewswire
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus
MELBOURNE, Australia and ATHENS, Greece, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive commercial distribution agreement with Athens-based BIOKOSMOS S.A. (BIOKOSMOS) for Telix’s prostate cancer investigational imaging product Illuccix® (Kit for the preparation of 68Ga-PSMA-11 injection) for the Greek and Cypriot markets. Under the terms of the agreement, BIOKOSMOS will be the overall distributo
- GlobeNewswire
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s prostate-specific membrane antigen (PSMA) targeting ‘ProstACT’ therapeutic program, which is exploring TLX591 in areas of unmet medical need across the full prostate cancer treatment journey. Telix’s ProstACT study program is evaluating the efficacy of Telix’s lutetium-177 (177Lu)-labelled therapeutic antibodie
- GlobeNewswire
Raphaël Ortiz Joins Telix as Chief Operating Officer, EMEA
MELBOURNE, Australia and LIÈGE Belgium, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Raphaël Ortiz has joined the Company as Chief Operating Officer for Europe Middle East and Africa (EMEA). Raphaël joins Telix with more than 20 years of pharmaceutical industry experience in a variety of roles, including in finance, business development, marketing and sales, as well as general management in Europe, Latin America and Asia. Pri
